Questcor Pharmacueticals (QCOR) Slammed 34% On Reports Aetna Insurance Coverage Dropped
Tweet
Share
E-mailGet Alerts QCOR Hot Sheet
Price: $93.60 --0%
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
5 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Questcor Pharmacueticals, Inc. (NASDAQ: QCOR) is now down 34 percent on reports from Citron Research that Aetna dropped coverage of key drug Acthar.
According to Cintron:
One of the largest managed care providers in the United States, Aetna has disclosed that after studies and review of scientific literature, it finds no proof of efficacy to substantiate reimbursement for Achtar, except for Infantile Spasms (West Syndrome).
Beginning Friday, September 14 Aetna will cease to offer reimbursement for new patients to use HP Acthar Gel, except for the rare indication of infantile spasms.
According to Cintron:
One of the largest managed care providers in the United States, Aetna has disclosed that after studies and review of scientific literature, it finds no proof of efficacy to substantiate reimbursement for Achtar, except for Infantile Spasms (West Syndrome).
Beginning Friday, September 14 Aetna will cease to offer reimbursement for new patients to use HP Acthar Gel, except for the rare indication of infantile spasms.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Equifax (EFX) shares tumble on weak Q1 revenue, guidance miss
- Zuora (ZUO) spikes into halt on takeover rumors
- Kaival Brands Innovations Group (KAVL) Halted on Volatility for Second Time, Up 150%
Create E-mail Alert Related Categories
Analyst Comments, Momentum Movers, Trading HaltsRelated Entities
Citron ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
